Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors
Authors:
- 1 March 2016
- journal article
- Published by Elsevier in Journal of Surgical Research
- Vol. 201 (1) , 38-43
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine NeoplasmJournal of Korean Medical Science, 2013
- Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine TumorsJournal of Hematology & Oncology, 2011
- Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor DiseaseAnnals of Surgical Oncology, 2010
- A simplified prognostic system for resected pancreatic neuroendocrine neoplasmsHPB, 2009
- Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid TumorsNeuroendocrinology, 2009
- Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single InstitutionClinical Cancer Research, 2008
- Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine TumorsGastroenterology, 2008
- Plasma Chromogranin A as Marker for Survival in Patients With Metastatic Endocrine Gastroenteropancreatic TumorsClinical Gastroenterology and Hepatology, 2008
- Orthotopic Liver or Multivisceral Transplantation As Treatment of Metastatic Neuroendocrine TumorsLiver Transplantation, 2007
- Octreotide Versus Octreotide Plus Interferon-Alpha in Endocrine Gastroenteropancreatic Tumors: A Randomized TrialClinical Gastroenterology and Hepatology, 2005